Here, we evaluated the efficacy of a series of six representative members of the ferrocifen family (P5, P15, P41, P53, P85, P722; Figure 1) selected from the 300 ferrocifens synthesized previously [13,21] in a panel of 15 GBM patient-derived cell lines (PDCLs) that were selected to represent the heterogeneity of GBMs encountered in the clinic (Table 1). Here, TP53 is linked to glioblastoma.